Insilico Medicine AI Drug Deals: Lilly and SK Biopharm Bet Big

Two Multibillion-Dollar Bets in Quick Succession

Insilico Medicine, the Hong Kong–listed AI drug discovery company, has signed its second headline-grabbing pharma partnership in a short span. The new agreement is with Korea's SK Biopharmaceuticals and focuses on neuroimmune conditions. It is valued at more than $2.5 billion if every milestone is met 1. It follows a deal with Eli Lilly worth up to $2.75 billion to bring some of Insilico's AI-discovered drugs to the global market 23.

Taken together, the two agreements carry a combined headline value of more than $5 billion. That is a striking number for a company that only went public in Hong Kong in December 3. As with most biopharma licensing deals, though, the headline figure and the cash that changes hands today are very different things.

How the Deals Are Structured

The SK Biopharmaceuticals pact divides the work along a familiar line. Insilico will use its Pharma.AI platform to design new drug candidates for neuroimmune treatments. SK Biopharmaceuticals will then lead late-stage development and commercialization 1.

Insilico is expected to receive about $18 million in near-term payments. The rest of the $2.5 billion depends on development and commercial milestones, with royalties on top 1. Fortune notes that this is Insilico's largest partnership to date with an Asia-Pacific company. It is also the second deal of this size the firm has struck with a major drugmaker 1.

The Lilly deal is more front-loaded. Lilly will pay Insilico $115 million upfront, within a total package of up to $2.75 billion 3. The agreement also grows out of an existing relationship, since the two companies have worked together since 2023 3. The large gap between the upfront payments ($115 million versus $18 million) suggests the partners value the assets differently, or that the programs are at different stages. The Lilly agreement appears to involve drugs Insilico has already developed, while the SK deal centers on discovering new candidates.

Market Reaction and Momentum

Investors have responded strongly. Insilico's shares jumped as much as 15% at the market open after the Lilly deal was announced. Bloomberg described it as the stock's strongest intraday rally in nearly two months 2. CNBC reported that the shares were up more than 50% year-to-date 3.

That performance matters for a recently listed company. Big-name partnerships act as outside validation, and they help support a valuation built largely on the promise of a technology platform rather than on approved products.

The Pipeline Behind the Pitch

Insilico's argument rests on scale. Zhavoronkov told CNBC the company has developed at least 28 drugs using generative AI tools, and nearly half are already at a clinical stage 3. He also offered a notable comment about his partner, saying Lilly has a competitive edge in certain aspects of AI 3. That suggests the collaboration is not a simple one-way transfer of technology from a startup to a traditional drugmaker.

His ambitions are not modest. "We want to be the SpaceX of the pharmaceutical industry," he told Fortune 1. The comparison implies a company aiming to reshape how drugs get made, not merely to sell discovery services.

There is one small discrepancy in the coverage. Fortune identifies Zhavoronkov as co-CEO 1, while CNBC calls him founder and CEO 3. The difference does not change the substance of the deals, but it is worth noting.

What It Means

The case for optimism is clear. Large drugmakers in both the U.S. and Asia are now signing sizable agreements built on Insilico's AI-driven approach. Lilly's decision to expand a relationship that began in 2023 is arguably a stronger signal than a first-time deal, because it reflects years of direct experience with the platform.

The case for caution is just as clear. Milestone-heavy deals let large pharma companies keep options open at low cost. If the programs fail, partners walk away having paid only the upfront fees. The SK deal's $18 million near-term figure, set against a $2.5 billion ceiling, illustrates this asymmetry. The real test of AI drug discovery is not deal value but whether candidates succeed in late-stage trials and reach patients.

On balance, these agreements mark Insilico's shift from a promising AI startup to a company that established drugmakers are willing to bet on publicly. Its next chapter will depend on clinical results rather than press releases. If even a few of its clinical-stage programs succeed, the SpaceX comparison may look less like bravado.